CYP2B6多态性对美沙酮代谢与儿科处置的影响:体外与体内研究
本研究通过体外共表达CYP2B6和POR变体评估美沙酮代谢,并对接受美沙酮手术的青少年进行基因分型与清除率测定。结果显示多种CYP2B6和POR变体在体外为慢代谢型,体内美沙酮清除率随CYP2B6慢代谢等位基因数量线性下降,而CYP2C19或POR*28不影响清除率。
要点
- CYP2B6慢代谢等位基因数量与美沙酮清除率线性负相关。
- CYP2B6 516G>T和983T>C为功能丧失变体,应纳入基因检测。
- CYP2C19和POR*28多态性不影响美沙酮体内清除率。
核心结论
- 多种CYP2B6和POR变体在体外降低美沙酮代谢速率。
- 体内美沙酮清除率随CYP2B6慢代谢等位基因数量增加而线性降低。
- CYP2C19慢或快代谢表型及POR*28携带状态不影响美沙酮清除率。
研究设计与样本
- 体外将CYP2B6和POR变体与细胞色素b5共表达,测定治疗浓度下美沙酮消旋体及对映体的代谢和内清除率。
- 体内对接受美沙酮手术的青少年进行CYP2B6、CYP2C19和POR基因分型,并测定美沙酮清除率和代谢物生成清除率。
主要发现
- CYP2B6.4活性高于野生型CYP2B6.1。
- CYP2B6.5、2B6.6、2B6.7、2B6.9、2B6.17、2B6.19和2B6.26活性降低。
- CYP2B6.16和2B6.18无活性。
- CYP2B6.1与POR.28、POR.5或P228L共表达时美沙酮代谢速率低于野生型还原酶。
- 体内美沙酮临床清除率随CYP2B6慢代谢等位基因数量线性下降。
关键数值与推荐
- CYP2B6 516G>T和983T>C编码经典功能丧失变体,考虑遗传对美沙酮临床处置影响时应进行评估。
临床怎么用
- 对于接受美沙酮治疗的患者,可考虑检测CYP2B6 516G>T和983T>C以评估遗传对美沙酮处置的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Methadone metabolism and clearance are determined principally by polymorphic cytochrome P4502B6 (CYP2B6). Some CYP2B6 allelic variants affect methadone metabolism in vitro and disposition in vivo. We assessed methadone metabolism by CYP2B6 minor variants in vitro. We also assessed the influence of CYP2B6 variants, and P450 oxidoreductase (POR) and CYP2C19 variants, on methadone clearance in surgical patients in vivo. METHODS: CYP2B6 and P450 oxidoreductase variants were coexpressed with cytochrome b5 . The metabolism of methadone racemate and enantiomers was measured at therapeutic concentrations and intrinsic clearances were determined. Adolescents receiving methadone for surgery were genotyped for CYP2B6, CYP2C19 and POR, and methadone clearance and metabolite formation clearance were determined. RESULTS: In vitro, CYP2B6.4 was more active than wild-type CYP2B6.1. CYPs 2B6.5, 2B6.6, 2B6.7, 2B6.9, 2B6.17, 2B6.19 and 2B6.26 were less active. CYPs 2B6.16 and 2B6.18 were inactive. CYP2B6.1 expressed with POR variants POR.28, POR.5 and P228L had lower rates of methadone metabolism than wild-type reductase. In vivo, methadone clinical clearance decreased linearly with the number of CYP2B6 slow metabolizer alleles, but was not different in CYP2C19 slow or rapid metabolizer phenotypes, or in carriers of the POR*28 allele. CONCLUSIONS: Several CYP2B6 and POR variants were slow metabolizers of methadone in vitro. Polymorphisms in CYP2B6, but not CYP2C19 or P450 reductase, affected methadone clearance in vivo. CYP2B6 polymorphisms 516G>T and 983T>C code for canonical loss of function variants and should be assessed when considering genetic influences on clinical methadone disposition. These complementary translational in vitro and in vivo results inform on pharmacogenetic variability affecting methadone disposition in patients.
引用
- Wang PF, Sharma A, Montana M, et al. Methadone pharmacogenetics in vitro and in vivo: Metabolism by CYP2B6 polymorphic variants and genetic variability in paediatric disposition. Br J Clin Pharmacol. 2022. PMID: 35538637. doi:10.1111/bcp.15393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。